Replies to post #2797 on Repros Therapeutics Inc (RPRX)

[io_io]

But it is likely good news, in that the price of the shares will be agreeable to both parties, and I assume it is tied to clinical progress. It should mean that RPRX can proceed down to the wire with the programs and without worrying about a short squeeze in advance of funidng.

[Bio_pete]

I was hoping the additional shares would be purchased on the open market in order to support the share price. Another 1.5 million shares could dry up all the trading.

[corpstrat]

<<I would imagine that an additional @ 1.5M shares will not affect many... especially if those shares come directly from the company.>>

You don't think fresh purchases of 1.5 mm shares - actually I get 1.66 mm shares for 13% of the outstanding - would put upward pressure on the stock price? Why not? Even if they are bought from Repros Treasury stock they help out the cash position, and it is likely that that cash question explains why the pps has been so miserable of late.

Their interests would seem to be aligned with other shareholders and management - get the best price at the right time - unless anyone knows something different.

Clearly if they lost heart and dumped all their stock they would cream the pps - just as buying takes us the other way. But they would be the biggest losers if they did this, so it won't happen lightly. And presumably there are some rules on this that go along with the standstill agreement. It's not ideal to be in the hands or judgment of a single player, but beggars can't be choosers. By the end of this year, if not well before, the information imperfections on Repros should be much reduced and then perhaps the market will attract some other buyers.